Pharma: Clinic Roundup
Monday, July 23, 2012
Bristol-Myers Squibb Co., of New York, said its candidate for liver cancer, brivanib, did not meet its primary overall survival objective based on a noninferiority statistical design in the Phase III BRISK-FL trial.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.